Rxrx stock forecast.
Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.
"Over the next 10 years, AI could increase productivity by 1.5% per year. And that could increase S&P500 profits by 30% or more over the next decade," Goldman Sach's senior strategist Ben Snider ...4.31%. €8.59M. RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Find the latest Insider Activity data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.The stock with a short interest of ~14% has added more than 92% this month, including a ~13% rise on Tuesday when ~7.2M company shares changed hands compared to the 65-day average of ~1.5M.
Find the latest GoodRx Holdings, Inc. (GDRX) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W ...What this means: Recursion Pharmaceuticals Inc Cl (RXRX) gets an Overall Rank of 60, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.
Track Recursion Pharmaceuticals Inc - Ordinary Shares - Class A (RXRX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsSep 20, 2022 · Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...
Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Welcome to Recursion: The Future of TechBio. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. It’s complex biology, decoded.The exchange reported a loss of $2.43 per share, compared to forecasts of a $2.52 loss per share, according to the FactSet consensus. Revenue plummeted 75% to $629.1 million, but still beat ...Recursion Pharmaceuticals (RXRX 7.88%) and Exact Sciences (EXAS 4.73%), two of Wood's larger biopharma holdings across her family of tech-oriented ETFs, are prime examples of the pros and cons ...Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
In the last three months, insiders have sold 333,493 shares of company stock worth $2,375,196. 19.96% of the stock is currently owned by insiders. Wall Street Analysts Forecast Growth
Zolak. Clinical-stage biotech Recursion Pharmaceuticals ( NASDAQ: RXRX) added ~7% in the pre-market Monday after announcing agreements to acquire Cyclica and Valence, two Canadian companies ...
The company raised guidance for annual organic revenue growth from an earlier forecast of between 5% and 7% to between 6% and 8%. It also raised annual adjusted EPS to be between $3.70 and $3.85 ...5 analysts have issued 12 month price objectives for Amneal Pharmaceuticals' stock. Their AMRX share price targets range from $3.00 to $7.00. On average, they anticipate the company's share price to reach $4.80 in the next year. This suggests a possible upside of 9.3% from the stock's current price.Planning a trip can be an exciting but challenging task. From booking accommodations to creating an itinerary, there are countless details to consider. One crucial aspect that should never be overlooked is checking the 7-day weather forecas...Nov 24, 2023 · The Recursion Pharmaceuticals, Inc. stock price gained 1.18% on the last trading day (Friday, 24th Nov 2023), rising from $6.78 to $6.86. During the last trading day the stock fluctuated 5.06% from a day low at $6.71 to a day high of $7.05. The price has risen in 7 of the last 10 days and is up by 31.17% over the past 2 weeks. Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Nov 22, 2023 · The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target for the stock is $15.57, which implies that it could rise by about 120% over the next 12 months. In particular, both Ginkgo Bioworks (NYSE: DNA) and Recursion Pharmaceuticals (NASDAQ: RXRX) are already implementing AI, and in the long term, it could be a crucial factor in their success.
NVIDIA Corporation Common Stock. $416.10 +5.93 +1.45%. ARM. Arm Holdings plc American Depositary Shares. $51.32 -0.84 -1.61%. Find the latest analyst research for Recursion Pharmaceuticals, Inc ...On the bottom line, Recursion's net loss per share of $0.38 remained flat compared to the prior-year quarter. The company ended the period with $405.9 million in cash and equivalents, which does ...A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.The Recursion Pharmaceuticals, Inc. stock price gained 7.88% on the last trading day (Friday, 1st Dec 2023), rising from $6.85 to $7.39. During the last trading day …Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.
Nov 28, 2023 · According to 6 stock analysts, the average 12-month stock price forecast for RXRX stock stock is $15.33, which predicts an increase of 120.26%. The lowest target is $8.00 and the highest is $33. On average, analysts rate RXRX stock stock as a buy. Analyst Forecast. According to 6 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $15.33, which is an increase of …
See Recursion Pharmaceuticals, Inc. (RXRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Weather forecasting plays a crucial role in our daily lives, helping us plan our activities and make informed decisions. But have you ever wondered how meteorologists are able to accurately predict the weather? One of the key components in ...60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.RXRX Stock 12 Months Forecast. Average Price Target. $16.60 (124.63% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Recursion ... Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...Dec 4, 2023 · The company, currently valued at $1.60B, closed the last trade at $7.39 per share which meant it gained $0.54 on the day or 7.88% during that session. The RXRX stock price is -126.66% off its 52-week high price of $16.75 and 38.57% above the 52-week low of $4.54. If we look at the company’s 10-day average daily trading volume, we find that it ... Sep 11, 2023 · Recursion Pharmaceuticals (RXRX 7.88%) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug ...
Recursion Pharmaceuticals, Inc. (RXRX) share price prediction for 2023, 2024, 2025, 2026 and 2027. RXRX one year forecast. Recursion Pharmaceuticals stock monthly and ...
Industry. Biotechnology. No executives to display. Corporate headquarters. --, --. Find real-time RXRX - Recursion Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN ...
60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock quote, history, news and other vital information to help you with your stock trading and investing.Stock Price Forecast. The 7 analysts offering 12-month price forecasts for Recursion Pharmaceuticals Inc have a median target of 14.00, with a high estimate of 35.00 and a low estimate of 9.00 ... Cathie Wood’s ARK Investment bought 1.89M shares of Recursion Pharmaceuticals November 27, 2023TipRanks. Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX ...Find the latest RxSight, Inc. (RXST) stock quote, history, news and other vital information to help you with your stock trading and investing.Forecast . Price target. 15.71 0.00 0.00%. The 7 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —. Analyst rating. Based on 7 analysts giving stock ratings to RXRX in the past 3 months. EPS. Annual Annual Quarterly Quarterly More MoreRXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more.60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Jul 13, 2023 · The US$14.13 analyst price target for RXRX is 3.5% ... we will estimate the stock's intrinsic value by taking the forecast future cash flows of the company and discounting them back to today's ... Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel ...The stock with a short interest of ~14% has added more than 92% this month, including a ~13% rise on Tuesday when ~7.2M company shares changed hands compared to the 65-day average of ~1.5M.
Explore RXRX - Recursion Pharmaceuticals Inc Stock Price Forecast: Accurate short-term and long-term price predictions up to 2050. ... Stock Calculator; Dow: 35,088. ...As of July 24, 2023, 4:00 PM CST, Recursion Pharmaceuticals Inc’s stock price was $14.28. Recursion Pharmaceuticals Inc is down 7.69% from its previous closing price of $15.47. During the last market session, Recursion Pharmaceuticals Inc’s stock traded between $14.36 and $16.09.Find the latest Earnings Report Date for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at ... Read our earnings report guide before you consider the forecast information when making ...Explore RXRX - Recursion Pharmaceuticals Inc Stock Price Forecast: Accurate short-term and long-term price predictions up to 2050. ... Stock Calculator; Dow: 35,088. ... Instagram:https://instagram. best shares for tradingfacet wealth management reviewsgmbl splitwine investors You can view all of the due diligence checks on RXRX's stock page. How is RXRX stock valued? You can. use many financial metrics, analyses, models, and charts to gauge RXRX's intrinsic value.Using relative valuations . metrics:RXRX; could be undervalued based on its P/B ratio of 3.35x, relative to Biotechnology industry P/B ratio of . 5.36xRecursion Pharmaceuticals Inc Cl A (RXRX) $7.05 0.38 (5.70%) 16:00 EST RXRX Stock Quote Delayed 30 Minutes. tastyworks pricinghow much are silver buffalo nickels worth 4.31%. €8.59M. RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Forecast . Price target. 15.71 0.00 0.00%. The 7 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —. Analyst rating. Based on 7 analysts giving stock ratings to RXRX in the past 3 months. EPS. Annual Annual Quarterly Quarterly More More eem ticker The 7 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —. Analyst rating Based on 7 analysts giving stock ratings to RXRX in the past 3 months. Sep 20, 2022 · Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...